Belgium· BE-AMP-SAM665012-00
Zemcelpro 0.23 10*6 cells/ml - 0.53 10*6 cells/ml
A stammzellen aus nabelschnurblut product containing dorocubicel, registered in Belgium by Cordex Biologics International. The same ATC class is registered in 8 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Stammzellen aus nabelschnurblut is registered in 8 of 19 countries.
Countries holding a registration under ATC B05AX04 (stammzellen aus nabelschnurblut), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Stammzellen aus nabelschnurblut · ATC B05AX04
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Dorocubicel
- Manufacturer
- Cordex Biologics International
- Country
- Belgium (BE)
- ATC code
- B05AX04
- ATC class
- Stammzellen aus Nabelschnurblut
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B05AX04
Stammzellen aus nabelschnurblut, as other registers publish it.
- PolandZemcelproCordex Biologics International Limited
- FinlandZemcelproCordex Biologics International Limited
- DenmarkZemcelproCordex Biologics International Limited
- IcelandZemcelproCordex Biologics International Limited
- CzechiaZEMCELPROCordex Biologics International Limited, Dublin
- NetherlandsZemcelpro ¿ 0,23 × 106 levensvatbare CD34+-cellen/ml / ¿ 0,53 × 106 levensvatbare CD3+-cellen/ml dispersie voor infusieCordex Biologics International Limited
- IrelandZemcelpro ≥ 0.23×106 viable CD34+ cells/mL/≥ 0.53×106 viable CD3+ cells/mL dispersion for infusionCordex Biologics International Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc0f11aa-9506-4a44-a8a8-0fe6378defd6 GET /v1/drugs/bc0f11aa-9506-4a44-a8a8-0fe6378defd6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Zemcelpro 0.23 10*6 cells/ml - 0.53 10*6 cells/ml",
"name_fr": "Zemcelpro 0.23 10*6 cells/ml - 0.53 10*6 cells/ml",
"name_nl": "Zemcelpro 0.23 10*6 cells/ml - 0.53 10*6 cells/ml",
"amp_code": "SAM665012-00",
"strengths": [
"0.2300",
"0.2300",
"0.5300",
"0.5300",
"10.0000",
"477.0000"
],
"pack_count": 1,
"substances": [
"Dorocubicel",
"Allogeneic Umbilical Cord-derived CD34- cells, Non-expanded",
"Dimethyl Sulfoxide",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Stem Cells From Umbilical Cord Blood",
"authorisation_numbers": [
"EU/1/25/1960/001"
]
}See everything about stammzellen aus nabelschnurblut.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.